Morning, Thursday, 18th October 2018
THIS EVENT IS CPD CERTIFIED
This seminar will consider the next steps in the development of biosimilars and their potential to generate cost-savings throughout the NHS.
Planned sessions will look at what lessons can be applied from the Cancer Vanguard in the adoption of biosimilars - as well as the wider impact of the Life Sciences Industrial Strategy in bringing new biological medicines to the market, and encouraging investment in biosimilar exports and manufacturing.
Further sessions will assess what more might be done to support the uptake of biosimilars in the NHS - including priorities for increasing engagement with clinicians, developing local commissioning frameworks and promoting patient choice.